NOVONIX Ltd Files 6-K Report

Ticker: NVNXF · Form: 6-K · Filed: May 30, 2024 · CIK: 1859795

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, reporting-update

Related Tickers: NVX

TL;DR

NOVONIX filed a 6-K, confirming 20-F annual report filing. Standard procedure.

AI Summary

NOVONIX Limited filed a Form 6-K on May 30, 2024, reporting for the month of May 2024. The filing indicates that the company will file its annual reports under Form 20-F. The company is incorporated in Australia and its principal executive office is located in Brisbane.

Why It Matters

This filing serves as an update for investors regarding NOVONIX's reporting status and confirms their adherence to SEC regulations for foreign private issuers.

Risk Assessment

Risk Level: low — This is a routine filing confirming reporting procedures and does not contain new financial or operational information.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer has made or is about to make public in its home country, has filed or is about to file with a stock exchange, or has distributed or is about to distribute to its security holders.

Which form will NOVONIX Limited use for its annual reports?

NOVONIX Limited will file its annual reports under cover of Form 20-F.

What is the filing date of this Form 6-K?

This Form 6-K was filed on May 30, 2024.

Where is NOVONIX Limited's principal executive office located?

NOVONIX Limited's principal executive office is located at Level 38, 71 Eagle Street, Brisbane, QLD 4000, Australia.

Does this filing contain specific financial results for the month of May 2024?

No, this Form 6-K is a report of foreign private issuer information and does not appear to contain specific financial results for May 2024; it primarily confirms reporting procedures.

Filing Stats: 198 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-05-30 09:28:42

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVONIX LIMITED By: /s/ Dr. John Christopher Burns Dr. John Christopher Burns Chief Executive Officer Date: May 30, 2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing